BCDA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BioCardia Inc (BCDA) is not a strong buy at this time for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is currently in a bearish technical trend, with no significant positive trading signals or catalysts to suggest a strong upward movement in the near term. The company's financials show declining performance, and there are liquidity concerns despite some progress in clinical trials. Given the lack of strong positive signals and the investor's preference for long-term stability, holding off on this stock is recommended.
The stock is in a bearish trend with MACD negatively expanding (-0.00702), RSI at 28.656 (neutral zone), and moving averages showing a bearish alignment (SMA_200 > SMA_20 > SMA_5). Key support is at 1.14, and resistance is at 1.251. The stock has a 70% chance of minor gains (up to 3.1%) over the next month, but this does not suggest a strong reversal.
Progress in CardiAMP therapy clinical trials with Phase III results showing meaningful treatment effects.
The company reported a significant net loss of $8.2 million for FY 2025, with EPS dropping by 62% YoY. Gross margin is at 0, raising concerns about profitability. Liquidity concerns persist with cash reserves at $2.5 million.
In Q4 2025, revenue remained at 0 with no YoY growth. Net income dropped to -$1.98 million (-13.59% YoY), EPS fell to -$0.19 (-62% YoY), and gross margin dropped to 0 (-100% YoY).
No analyst rating or price target changes were provided. Wall Street sentiment is neutral with no significant pros or cons highlighted.
